OncoMatch

OncoMatch/Clinical Trials/NCT07121946

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

Is NCT07121946 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including LTZ-301 and LTZ-301 for non-hodgkin lymphoma refractory/ relapsed.

Phase 1RecruitingLTZ Therapeutics, Inc.NCT07121946Data as of May 2026

Treatment: LTZ-301 · LTZ-301 · LTZ-301 — This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-Hodgkin lymphoma

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 2 prior lines

Cannot have received: allogeneic stem cell transplant

Prior allogeneic stem cell transplant

Cannot have received: autologous stem cell transplant

Exception: within 100 days prior to the first LTZ-301 administration

ASCT within 100 days prior to the first LTZ-301 administration

Cannot have received: CAR-T cell therapy

Exception: within 60 days prior to the first LTZ-301 administration

Prior CAR-T within 60 days prior to the first LTZ-301 administration

Cannot have received: solid organ transplant

Prior solid organ transplant

Lab requirements

Blood counts

adequate bone marrow function

Kidney function

adequate renal function

Liver function

adequate hepatic function

Cardiac function

adequate cardiac function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • City of Hope · Duarte, California
  • Washington University School of Medicine · St Louis, Missouri
  • Roswell Park Cancer Institute · Buffalo, New York
  • Tennessee Oncology · Nashville, Tennessee
  • Fred Hutchinson Cancer Center · Seattle, Washington

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify